```json
{
"content": [
{
"type": "paragraph",
"content": "The Electronic Pupillometer market is partitioned primarily by clinical application, a classification that directly shapes revenue distribution. Neurology accounts for the largest share, roughly 35 % of total sales, driven by demand for quantitative pupil assessment in traumatic brain injury and stroke monitoring. Ophthalmology follows with an estimated 30 % share, reflecting routine use in glaucoma screening and cataract surgery pre‑assessment. Anesthesiology contributes about 15 % as intra‑operative pupil monitoring supports depth‑of‑anesthesia decisions. Sports Medicine and Research each represent approximately 10 % of the market, the former leveraging pupillometry for concussion protocols and the latter sustaining product innovation through academic studies. Forecasts 2024‑2030 project a CAGR of 7 % for neurology, versus 5 % for ophthalmology, reflecting higher reimbursement and expanding neuro‑critical units. Sports medicine and research show modest 3 % CAGR, limited by reimbursement and grant funding. These divergent trajectories illustrate why application‑level analysis is essential for investors. Collectively, these application segments account for the full market revenue, with neurology and ophthalmology together representing roughly two‑thirds of total sales, thereby driving the bulk of R&D investment and pricing power. Regionally, North America captures the largest proportion of neurology sales due to mature hospital networks, while Europe leads in ophthalmology adoption, reflecting differing regulatory pathways."
},
{
"type": "paragraph",
"content": "The Electronic Pupillometer market is also
